Introduction {#s1}
============

Obesity is an important risk factor for prevalent chronic health complications, such as type 2 diabetes (T2D) and cardiovascular disease. At the nexus of obesity-related co-morbidities is insulin resistance, which is characterized by a reduced responsiveness of insulin-sensitive tissues such as skeletal muscle, adipose tissue and liver to insulin-mediated glucose and lipid metabolism. Insulin resistance in skeletal muscle is considered especially pathogenic, as this tissue accounts for the majority of insulin-stimulated glucose disposal [@pone.0028577-Defronzo1]. Accumulation of intramuscular lipid and excess plasma free fatty acid levels are considered central to aberrant skeletal muscle insulin signaling [@pone.0028577-AbdulGhani1]. The pro-inflammatory state associated with obesity [@pone.0028577-Dandona1] is also implicated as a factor in skeletal muscle insulin resistance [@pone.0028577-Bastard1], [@pone.0028577-Hotamisligil1].

Expanded visceral fat, as opposed to subcutaneous fat, is more strongly associated with insulin resistance and various comorbidities, especially cardiovascular disease, hypertension and hyperlipidemia [@pone.0028577-Chiba1], [@pone.0028577-McLaughlin1], [@pone.0028577-Rosito1], [@pone.0028577-Veilleux1], [@pone.0028577-Despres1]; it is also considered an important source of systemic free fatty acid (FFA) overload and inflammation due to enhanced lipolysis, cytokine secretion [@pone.0028577-Ibrahim1], [@pone.0028577-Lafontan1], and macrophage infiltration [@pone.0028577-HarmanBoehm1]. Based on the available literature, it is clear that visceral fat is associated with insulin resistance. Our recent findings show that removal of the omentum with RYGB does not impart any additional benefits on hepatic insulin sensitivity or on insulin induced peripheral (muscle) glucose utilization [@pone.0028577-Fabbrini1]. However, these observations do not rule out any beneficial effects of removal of visceral fat on other muscle-mediated variables that could influence muscle glucose utilization. Recently, Varma *et al.* provided evidence that pro-inflammatory macrophages infiltrate skeletal muscle of obese, insulin-resistant humans and are activated by fatty acids [@pone.0028577-Varma1], suggesting that local inflammation might be causative of skeletal muscle insulin resistance. Elevated proinflammatory cytokines such as TNF-α as well as increased proinflammatory pathway activation such as NFκB signaling through IκB kinase (IKK) and JNK-mediated phosphorylation of IRS-1 are also observed in various models of obesity induced insulin resistance [@pone.0028577-Hotamisligil2], [@pone.0028577-Arkan1], [@pone.0028577-Itani1], [@pone.0028577-Yuan1]. These observations suggest local inflammation in muscle as a possible mechanism by which the effects of insulin may be governed.

RYGB surgery results in 40% weight loss and resolution of T2D in 80% of patients by one year after surgery [@pone.0028577-Buchwald1]; additionally, skeletal muscle insulin sensitivity is improved ∼two-fold [@pone.0028577-Fabbrini1], [@pone.0028577-Pereira1]. Relatively few studies have examined the effect of RYGB on muscle lipid content [@pone.0028577-Gray1], [@pone.0028577-Houmard1] and insulin signaling proteins [@pone.0028577-Friedman1], [@pone.0028577-Pender1]. One study revealed a differential expression of genes involved in insulin signaling (growth factor receptor-bound protein 14; GRB14), triglyceride synthesis (glycerol-3-phosphate dehydrogenase 1; GPD1), and muscle mass (myostatin; GDF8) by performing microarray analysis on muscle biopsies from 3 subjects obtained before and 12 months after gastric bypass surgery [@pone.0028577-Park1]. In the current study, we report the effects of RYGB combined with omental fat removal on skeletal muscle glucose utilization and on gene expression profiles, especially those related to the inflammatory pathways. Serial skeletal muscle biopsies and hyperinsulinemic-euglycemic clamps were performed preoperatively and at 6 and/or 12 months post-RYGB in 21 obese subjects undergoing RYGB and randomized to omentectomy.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

All subjects provided written, informed consent before participating in this study, which was approved by the Health Sciences Committee of the Vanderbilt University Institutional Review Board.

Subjects {#s2b}
--------

Obese men and women between 18 and 60 years old, with and without T2D, and with physician\'s approval for RYGB, were recruited from the Center for Surgical Weight Loss at Vanderbilt University Medical Center (Nashville, TN). The cohorts consisted of 13 subjects receiving RYGB surgery plus omentectomy (11 women and 2 men, 44±8 years old, 7 with T2D) and 8 subjects receiving RYGB surgery alone (7 women and 1 man, 40±11 years old, 6 with T2D, see [**Figure 1**](#pone-0028577-g001){ref-type="fig"} and [**Table 1**](#pone-0028577-t001){ref-type="table"}). Diabetic subjects using oral anti-diabetic agents were asked to discontinue all medications for 5 days prior to each study visit.

![CONSORT Diagram.](pone.0028577.g001){#pone-0028577-g001}

10.1371/journal.pone.0028577.t001

###### Effect of Roux-en-Y Gastric Bypass surgery with or without omentectomy on body composition and metabolic variables.

![](pone.0028577.t001){#pone-0028577-t001-1}

  Category                       Before surgery   6 months post-op   12 months post-op    P value                                           
  ----------------------------- ---------------- ------------------ ------------------- ----------- ----------- ----------- ------- ------- ---------
  Gender (F/M)                        7/1               11/2                6/1            10/2         7/1         6/2                     
  Ethnicity (Cau/AfAm)                6/2               9/4                                                                                 
  Diabetes (N/Y)                      2/6               6/7                 2/5             5/7         2/6         3/5                     
  Weight (kg)                        129±22            137±17              97±16           98±13       87±16       89±8      0.311   0.191   \<0.001
  Body mass index (kg/m^2^)         46.3±6.2          49.6±8.6           34.3±4.8        34.8±5.7    31.1±4.5    31.8±4.7    0.291   0.174   \<0.001
  Fat mass (kg)                      62±13             62±11               42±12           40±9        33±11       34±8      0.924   0.691   \<0.001
  Lean mass (kg)                     64±12             67±11               53±14           54±9        50±11       52±8      0.538   0.353   \<0.001
  Body fat (%)                        48±5              47±5               43±7            42±6        38±8        39±7      0.661   0.478   \<0.001
  Glucose (mg/dL)                    141±52            133±44              93±15           96±10       92±13      107±50     0.601   0.455   \<0.001
  Insulin (mU/L)                     29±14             24±12               8 ± 5            8±3         8±4         7±4      0.239   0.504   \<0.001
  Glycosylated hemoglobin (%)       6.3±0.7           6.6±0.8             5.7±0.8         5.8±0.5     5.7±0.5     6.0±1.4    0.706   0.843   \<0.001
  Free fatty acids (mmol/L)        0.64±0.12         0.70±0.23           0.65±0.23       0.60±0.15   0.53±0.08   0.58±0.16   0.731   0.905    0.054
  Total triglyceride (mg/dL)         155±67            148±91              94±43           83±29       83±35       81±25     0.723   0.679   \<0.001
  Leptin (ng/mL)                     36±13             35±10               20±12           16±5        17±12       13±9      0.701   0.507   \<0.001
  Total adiponectin (µg/mL)         7.5±5.0           8.1±6.6             9.8±3.7        11.0±4.3    18.6±9.7    13.4±8.3    0.508   0.096   \<0.001
  M (mg/kg·min)                     4.4±1.8           4.8±1.3             6.9±2.0         8.6±1.5     8.9±1.9     9.5±2.2    0.287   0.917   \<0.001
  M/I (mg·mL/kg·min·mU)             16.0±9.3         21.1±13.9           32.8±13.5       35.3±13.3   36.8±14.5   37.2±10.4   0.367   0.595   \<0.001

Values are means ± SD; P values for the main effects of group and time and their interaction (G×T) are reported. M, glucose disposal rate per kg of body weight; M/I, insulin sensitivity index (M-value per unit of plasma insulin).

Study Protocol {#s2c}
--------------

We conducted a 12-month randomized, controlled trial wherein subjects underwent RYGB with or without omentectomy. Studies were conducted preoperatively and at 6 and 12 months post-RYGB at the Vanderbilt Clinical Research Center (CRC) between March 2005 and December 2008. The protocol for this trial and the CONSORT checklist are available as supporting information (**[Protocol S1](#pone.0028577.s002){ref-type="supplementary-material"}** and **[Checklist S1](#pone.0028577.s001){ref-type="supplementary-material"}**). Randomization was conducted using a computer generated code with a permuted block size of four. Separate randomization codes were used for Caucasian females, Caucasian males, African American females, and African American males to achieve equal gender and ethnic distributions in each group. The study coordinator generated the random allocation sequence and notified the surgeon at the beginning of the surgical procedure of the patient\'s randomization category. All recruited participants and researchers involved in the conduct of the study and sample analysis were blinded to treatment. The primary outcome measure in this study was insulin sensitivity as measured by the hyperinsulinemic euglycemic clamp [@pone.0028577-Fabbrini1], and a secondary outcome measure was gene expression in skeletal muscle biopsies. Enrollment was concluded when we obtained sufficient power for the primary outcome measure.

Muscle insulin sensitivity was estimated using a hyperinsulinemic euglycemic clamp as the rate of exogenous dextrose (20%) infusion to maintain euglycemia (plasma glucose of 90--100 mg/dl) during a high-dose insulin infusion (2--3 mU/kg.min). The clamp studies were performed in all subjects at three time points: (a) In the preoperative period, at least one week prior to the surgical procedure, and at (b) 6-months and (c) 12 months postoperatively. Muscle biopsies were acquired from the *vastus lateralis* muscle using a Bergstrom needle as previously described [@pone.0028577-Fabbrini1]. Basal (prior to RYGB) muscle biopsies were obtained from all subjects (n = 21) at the time of the surgical procedure, immediately after adequate induction of general anesthesia and prior to initiation of the RYGB procedure. The postoperative muscle biopsies were obtained on the CRC on the day of and prior to initiation of the insulin clamp, using 1% Lidocaine solution as local anesthetic. Fourteen subjects had muscle biopsies at the three specified time points (pre-RYGB and at 6 and 12 months post-RYGB); 5 subjects had muscle biopsies obtained during the basal period and at 6 months post-RYGB, and 2 subjects had biopsies performed during the basal period and at 12 months post-RYGB. Biopsy specimen were dissected free of fat and vasculature, blotted free of blood and immediately snap frozen in liquid nitrogen and stored at −80°C until analyzed. The surgical procedure consisted of a laparoscopic RYGB surgery, in which a small gastric pouch (∼25 ml) was created and a Roux-en-Y gastrojejunostomy with a 30- to 50-cm biliopancreatic limb and a 100- to 200-cm Roux limb was constructed. In patients randomized to receive an omentectomy, surgeons resected an average of 0.74 kg of greater omentum [@pone.0028577-Fabbrini1].

Blood was collected and assays were performed as previously described [@pone.0028577-Fabbrini1]. The inflammatory cytokines monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-1β, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-α were measured by multiplex BD™ Cytokine Bead Array combined with flow cytometry (BD Biosciences, San Diego, California). Fat and lean body mass were assessed with dual-energy x-ray absorptiometry (GE Lunar Prodigy, Madison, WI) using half-body scans[@pone.0028577-Tataranni1].

RNA isolation {#s2d}
-------------

Skeletal muscle biopsies were chopped into small pieces at −20°C and 1 ml Trizol (Invitrogen, Carlsbad, CA) was added per 100 mg of sample. RNA was extracted using Qiagen\'s RNase-free DNase Set (Valencia, CA) supplied protocol with the following modification. RNA was precipitated with 0.25 volumes isopropanol (Fisher Scientific, Fairlawn, NJ) and 0.25 volumes of RNA precipitation solution (7% NaCl/21% disodium citrate). DNase treatment was performed by adding 10 µl DNase and 70 µl Buffer RDD (Qiagen) per 100 µl sample. Trizol isolation was repeated once or twice to remove the DNase and any remaining fats or salts. RNA was re-suspended in RNase/DNase free water.RNA quality was assessed by the Vanderbilt Microarray Shared Resource on an Agilent 2100 Bioanalyzer utilizing RNA integrity numbers (RINs), 260/280 absorption and 28 s∶18 s ratios [@pone.0028577-Pollins1]. RNA samples included in this experiment exceeded the recommended RIN of 6, with an average RIN of 7.4.

Generation of cDNA {#s2e}
------------------

To minimize costs, initial gene expression profiles of muscle RNA pools were determined using Affymetrix GeneChip Human Exon 1.0 ST arrays. Skeletal muscle RNA pools (pre-RYGB, 6 months post-op, and 12-months post-op) from RYGB subjects with and without omentectomy (6 pools total) were prepared from 42 different skeletal muscle RNA samples. RNA samples were prepared for microarray analysis using the standard Affymetrix protocol (Affymetrix Inc., Santa Clara, CA) and published techniques [@pone.0028577-Brem1], [@pone.0028577-Dasu1]. Briefly, 200 ng pooled total RNA and poly-A spike in controls, were brought to 5 µl with nuclease free water. First Strand Synthesis Master mix was added to the sample mix and incubated at 42°C for 1 hr; enzymes were heat inactivated 10 minutes at 70°C, followed by a cooling to 4°C for 2 minutes. Subsequently, second strand synthesis master mix was added to the sample mix and incubated at 16°C for 2 hours. The reactions were heat-inactivated by 10 minute incubation at 75°C. The resulting cDNA was then processed in an IVT reaction to generate cRNA that was used in first strand synthesis reactions to generate targets of the correct sense for hybridization to the Affymetrix Exon arrays. The reactions were set up with 10 µg cRNA, random hexamer, and first strand synthesis reagents to make cDNA. The targets were then treated with RNAse to remove template RNA and cleaned up over kit supplied columns, or Agencourt SPRI beads, following manufacturer\'s protocol. A total of 5.5 µg of the clean cDNA target was then enzymatically fragmented and end-labeled using the Affymetrix kit reagents. The cRNA, cDNA, and fragmented and end-labeled targets were assessed by Agilent bioanalysis to ensure that the amplified targets met the recommended smear range, and that fragmentation and end-labeling were complete.

Microarray Hybridization {#s2f}
------------------------

The requisite amount of target was then added to hybridization cocktail to give a final target concentration of ∼25 ng/µl in the hybridization cocktail. The targets in hybridization cocktail were heat denatured at 99°C for 5 minutes, cooled to 45°C for 5 minutes, centrifuged and then loaded on the Affymetrix cartridge arrays for a hybridization period of 16 hours at 45°C, with rotation of 60RPM in the Affymetrix Model 645 Hybridization Oven. The cartridge arrays were washed, and stained per standard Affymetrix Protocols using Affymetrix Hybridization Wash and Stain kit reagents. After washing and staining, the arrays were scanned in an Affymetrix 7G plus scanner. The resulting data was acquired by GCOS software.

Validation by Taqman Low Density Array {#s2g}
--------------------------------------

To validate the expression levels of probes from RNA analyses, the 42 individual RNA samples comprising the pool were analyzed using Taqman Low Density Array (TLDA) [@pone.0028577-Greco1]. An additional 12 skeletal muscle RNA samples not previously analyzed by microarray (baseline and post-RYGB in seven additional subjects) also were included. Total RNA (500 ng) was reverse transcribed to ds cDNA using random primers, SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA) according to the supplied protocol. Following reverse transcription, each 20 µl reaction was diluted with 25 µl of DNase/RNase-free water. Quantitative PCR was then performed using 500 ng of cDNA per reaction well. Thirty-one experimental genes and one control gene were assayed by qPCR. Thirty-two gene specific assays were purchased from Applied Biosystems (Foster City, CA) as custom TLDA microfluidics cards (Format 32) with TLDA probes (**[Table S3](#pone.0028577.s005){ref-type="supplementary-material"}**) spotted in triplicate on 384 well plates. All reactions were carried out at the following thermocycling conditions: Step 1: 10 min at 95°C, Step 2: 40 cycles of 15 s at 95°C, and Step 3: 1 min at 60°C. An Applied Biosystems ABI 7900HT unit with automation attachment (Foster City, CA) was used for real-time PCR. This unit is capable of collecting spectral data at multiple points during a PCR run.

Statistical Quality Control, Methods and Bioinformatics {#s2h}
-------------------------------------------------------

The sample size for the current study was dictated by availability of a baseline and at least one postoperative muscle biopsy collected from the parent study [@pone.0028577-Fabbrini1]. The study power analysis was completed using the general linear model. A sample size of at least 7 patients per condition per time point, provided at least 90% power to detect an effect size of 4, i.e., 4-fold change, with two-sided false discovery rate (FDR) of 0.05.

Anthropometric and metabolic parameters were analyzed for an effect of time and group (omentectomy) using linear mixed effects models in IBM SPSS version 18 (Chicago, IL). The overall intensities of all probes across the six microarrays were subjected to box plot analysis ([**Figure 2**](#pone-0028577-g002){ref-type="fig"}). Exon ST 1.0 array data pre-processing was done using GeneSpring v7.3 software (Agilent Technologies, Foster City, CA). Probe-level analysis was performed using the Robust Multichip Analysis (RMA) method [@pone.0028577-Irizarry1], but the default quantile across-sample normalization method of RMA was not done in order to avoid over-correction for the small sample size. The expression values were in log~2~ format after RMA. The change between samples was calculated as the difference between the two expression values. Winner probes for each comparison were selected based on two stringency criteria: a cutoff of 2 fold (2,697 genes, used for global pathway analysis; **[Table S1](#pone.0028577.s003){ref-type="supplementary-material"}**) or 4-fold change (103 genes, subset selected for TLDA validation; **[Table S2](#pone.0028577.s004){ref-type="supplementary-material"}**). Relative quantitation and standard deviation calculations with TLDA data were performed by the comparative *C* ~T~ method [@pone.0028577-Livak1]. The 56 cDNA samples were assayed in triplicate for each gene of interest and the control. For each gene in each sample, the average *C* ~T~ and the standard deviation were calculated, and the 18S control average *C* ~T~ was subtracted from the gene average *C* ~T~. The resulting value is the Δ*C* ~T~. The standard deviation for the Δ*C* ~T~ was calculated by taking the square root of the sum of the control and gene standard deviations. For comparisons to basal time points, the average Δ*C* ~T~ for the basal period pools was subtracted from the respective average Δ*C* ~T~ of the 6 and 12 months samples generating a ΔΔ*C* ~T~. Fold changes between conditions are given by applying the expression 2^−ΔΔCT^, and ΔΔ*C* ~T~ ± standard deviation applied to this expression gives the range. Correlation analysis was implemented using the "stat" package under R2.12.1 [@pone.0028577-Team1] without adjustment for multiple comparisons.

![Box plot depicting the difference among microarray expression datasets (chips) before and after normalization by Robust Microarray Averaging (RMA).\
Boxes show the 25th and 75th percentiles in the distribution of log-transformed (log base 2) intensities. The median is the horizontal bar in the middle of the box. The whiskers (dotted lines extending from the boxes) illustrate the maximum value or 1.5 times the interquartile range of data (IQR), whichever is smaller. The circles display any points beyond these whiskers.](pone.0028577.g002){#pone-0028577-g002}

Results {#s3}
=======

Participant Flow, Recruitment, and Numbers Analyzed {#s3a}
---------------------------------------------------

Fifty-six of 300 screened subjects were enrolled in the trial ([**Figure 1**](#pone-0028577-g001){ref-type="fig"}). Twenty-one subjects completed all study components at all time points (pre-surgery, 6 and 12 month post-operative) and yielded a complement of muscle RNA samples of sufficient quality (average RIN of 7.4) to have expression analysis performed. The first participant was enrolled in March, 2005.

Anthropometric and Metabolic Parameters {#s3b}
---------------------------------------

Both the omentectomy and non-omentectomy groups exhibited significant decreases in body weight, BMI, fat mass, and lean mass during the 12 months after RYGB; there was neither a group effect nor a group×time interaction ([**Table 1**](#pone-0028577-t001){ref-type="table"}). Amount of initial weight lost was 28±3% in the first 6 months and 34±6% in 12 months following surgery across both groups. Similarly, fasting levels of glucose, insulin, triglycerides, leptin, and adiponectin were significantly decreased and free fatty acids were marginally decreased over time without a group or group×time effect. Insulin-stimulated glucose uptake in the muscle was significantly increased ∼2-fold by 12 months after RYGB in both groups, without significant differences between groups or group×time interactions.

Circulating Inflammatory Markers {#s3c}
--------------------------------

A main effect of time post-RYGB was detected for systemic concentrations of CRP and MCP-1 but not for IL-1β, IL-6, IL-8, IL-10, nor TNF-α. There was no effect of omentectomy or group×time interaction for any inflammatory cytokine ([**Table 2**](#pone-0028577-t002){ref-type="table"}).

10.1371/journal.pone.0028577.t002

###### Serological measures of inflammation determined before and after RYGB with and without omentectomy.
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  Category                      Before surgery   6 months post-op   12 months post-op    P value                                            
  ---------------------------- ---------------- ------------------ ------------------- ----------- ----------- ------------ ------- ------- ---------
  C-reactive protein (µg/mL)       11.0±9.1          9.3±11.0            2.4±1.4         3.2±3.6     2.8±3.8     1.0±0.5     0.716   0.983   \<0.001
  IL-1β (pg/ml)                    2.9±4.6          18.6±38.5            2.2±1.2        6.2±10.5     1.9±1.4    16.2±34.5    0.194   0.119    0.06
  IL-6 (pg/ml)                     3.1±2.0          62.5±190.5           5.4±4.7        10.9±21.5    4.4±6.6    62.1±159.7   0.299   0.085    0.114
  IL-8 (pg/ml)                     3.7±2.1          18.6±45.4            3.3±1.4         8.5±9.0     3.8±1.7    19.6±38.8    0.265   0.246    0.263
  IL-10 (pg/ml)                    1.8±1.0           3.8±4.4             1.9±0.9         1.9±1.1     1.3±0.5     2.0±0.7     0.106   0.316    0.089
  MCP-1 (pg/ml)                   85.9±71.1        135.5±209.4          70.4±66.8       59.8±52.9   57.4±49.1   97.9±175.7   0.087   0.41     0.001
  TNF-a (pg/ml)                    1.8±1.7          12.1±23.3            1.8±1.0         4.7±7.4     1.2±0.6     9.4±15.7    0.123   0.18     0.119

Overview of skeletal muscle gene expression patterns after RYGB with and without omentectomy {#s3d}
--------------------------------------------------------------------------------------------

We compared skeletal muscle gene expression patterns between two surgical groups (RYGB surgery with no omentectomy vs. RYGB surgery with omentectomy) over time (6 vs. 0 months, and 12 vs. 0 months) in six skeletal muscle RNA sample pools derived by combining equal amounts of RNA from 7 subjects at each time point. For each time point, the observed gene expression value was compared to an overall average expression value derived from the union of all probe intensities (33,297) across all six Affymetrix Human Exon 1.0 ST Arrays. Probe intensities were then log~2~ transformed, and those genes expressed greater than 2 fold (log~1~ = 4 fold) within any time-point comparison were collated. In this manner, not all genes expressed were changed greater than 2-fold among all time-points. Expression levels of the 2,697 probes in each of the 6 microarrays changed greater than 2 fold after hierarchical clustering analysis is displayed graphically in [**Figure 3**](#pone-0028577-g003){ref-type="fig"} and individual expression values are listed in **[Table S2](#pone.0028577.s004){ref-type="supplementary-material"}**. While significance cannot be derived from these microarray hybridizations without experimental replication, general expression were noted. For example, groups without (No) and with (Yes) omentectomy displayed similar expression profiles at 0 months. Additionally, most genes downregulated at 0 month were upregulated at 6 months, and conversely most genes upregulated at 0 month were downregulated at 6 months. At 12 months in both the omentectomy and non-omentectomy groups, the overall abundance of genes changing more than 2-fold was diminished, with no apparent differences as a function of omentectomy.

![Heat map displaying hierarchical clustering results from microarray expression profile data derived from skeletal muscle RNA pools.\
Samples include 0, 6 and 12 months "No" omentectomy and 0, 6 and 12 months "Yes" omentectomy. The expression of 2,697 genes is represented as a dendrogram after applying filtering criteria for selecting genes with a log~2~ ratio intensity greater than 1 (ratio\>2). Gene expression ratios are displayed by applying progressively brighter shades of red (down-regulated) or green (up-regulated) to log~2~ ratios that increasingly deviate from zero.](pone.0028577.g003){#pone-0028577-g003}

Skeletal muscle gene expression changes without omentectomy {#s3e}
-----------------------------------------------------------

To identify those genes with the greatest change in expression after RYGB we compared genes with greater than 2-fold (log~2~) changes in expression. [**Table 3**](#pone-0028577-t003){ref-type="table"} lists those 25 genes that were differentially expressed comparing 6 vs. 0 months without omentectomy. The AP-1 transcription factors such as FOS, FOSB, JUNB as well as MYC and EGR1 were among those downregulated to the greatest degree at 6 months. These are immediate early genes acting on a specific biological response that directly induces or controls a variety of other genes [@pone.0028577-Puntschart1]. HOXC10, a gene associated with muscle satellite cell activation, was the only transcription factor that was upregulated [@pone.0028577-Gabellini1]. Genes regulating various cellular processes averaged a greater than 5-fold downregulation: *inflammation* (ANKRD1, CDR1, CCL2, IL6, MAOB, GADL1, ITLN1); *protein turnover* (IGFN1, FBXW10); and *extracellular matrix remodeling* (CYR61, THBS1, THBS4). The small nucleolar RNA C/D box genes SNORD115-44, SNORD25, and SNORD59B were among those genes which were upregulated at 6 months without omentectomy.

10.1371/journal.pone.0028577.t003

###### Genes changed ≥4 fold (log 2 base ≥2) between 6 and 0 months no omentectomy.
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  Probe ID    Gene Symbol                      Gene Description                                 Process                 Cytoband     mRNA Accession    log2fold
  ---------- ------------- -------------------------------------------------------- -------------------------------- -------------- ----------------- ----------
  7955858       HOXC10                           homeobox C10                             transcription factor          12q13.3         NM_017409      2.05587
  8148317         MYC            v-myc myelocytomatosis viraloncogene homolog             transcription factor          8q24.21         NM_002467      −2.0047
  8026047        JUNB                        jun B proto-oncogene                         transcription factor          19p13.2         NM_002229      −2.0214
  8029693        FOSB          FBJ murine osteosarcoma viraloncogene homolog B            transcription factor          19q13.32        NM_006732      −2.17407
  8108370        EGR1                      early growth response 1                        transcription factor           5q31.1         NM_001964      −2.5463
  7975779         FOS        v-fos FBJ murine osteosarcoma viraloncogene homolog          transcription factor          14q24.3         NM_005252      −3.14739
  7981990        PWCR1            Prader-Willi syndrome chromosome region 1          small nucleolar RNA expression     15q11.2         NR_003106      2.53618
  7964246      SNORD59B                small nucleolar RNA, C/D box 59B              small nucleolar RNA expression     12q13.3         NR_003046      2.49785
  7982094     SNORD115-44            small nucleolar RNA, C/D box 115-44             small nucleolar RNA expression     15q11.2         NR_003359      2.43735
  7948910       SNORD25                small nucleolar RNA, C/D box 25               small nucleolar RNA expression      11q13          NR_002565      2.09656
  8012949       FBXW10          F-box and WD repeat domaincontaining 10, mRNA               protein turnover             17p12       ENST00000308799   2.30938
  7908650        IGFN1                      eEF1A2 binding protein                          protein turnover             1q32.1         NM_178275      −2.25232
  8090872         KY                       kyphoscoliosis peptidase                              other                   3q22.2         NM_178554      2.06643
  8175311       CXorf48     chromosome X open reading frame48 transcript variant 2               other                   Xq26.3      ENST00000344129   −2.09328
  8156848        NR4A3         nuclear receptor subfamily 4, group A, member 3              orphan receptor               9q22          NM_173198      −2.75007
  8085972        GADL1                  glutamate decarboxylase-like 1                     insulin signaling           3p24.1-p23       NM_207359      2.26062
  7921690        ITLN1        intelectin 1 (galactofuranose binding) (omentin-1)           insulin signaling           1q22-q23.5       NM_017625      −2.40258
  8172204        MAOB                        monoamine oxidase B                              inflammation              Xp11.23         NM_000898      2.08435
  8131803         IL6                 interleukin 6 (interferon, beta 2)                      inflammation                7p21          NM_000600      −2.27324
  8006433        CCL2               chemokine (C-C motif) ligand 2 (MCP-1)                    inflammation            17q11.2-q12       NM_002982      −2.3367
  8175531        CDR1          cerebellar degeneration-relatedprotein 1, 34kDa                inflammation            Xq27.1-q27.2      NM_004065      −2.51038
  7934979       ANKRD1             ankyrin repeat domain 1 (cardiac muscle)                   inflammation              10q23.31        NM_014391      −3.16087
  7982597        THBS1                         thrombospondin 1                       extracellular matrix protein       15q15          NM_003246      −2.11267
  8106573        THBS4                         thrombospondin 4                       extracellular matrix protein        5q13          NM_003248      −2.23557
  7902687        CYR61              cysteine-rich, angiogenic inducer, 61             extracellular matrix protein      1p31-p22        NM_001554      −2.78682

[**Table 4**](#pone-0028577-t004){ref-type="table"} lists the 36 genes that were most changed at 12 vs. 0 months in the RYGB without omentectomy cohort underscoring the durability of these responses. Several of the genes downregulated at 6 vs. 0 months without omentectomy also were observed at this time point, including the AP-1 transcription factors, markers of satellite cell activation, genes facilitating the inflammatory response, (CCL2, CDR1, and IL6), and the orphan receptor NR4A3, as well as genes regulating extracellular matrix formation and protein turnover. Additionally, over 20 genes regulating small nucleolar RNA (snoRNA) expression, mostly from the C/D box 115 group, were upregulated. SnoRNAs are not transcribed into protein products; they influence the structure of other mRNAs and their encoded proteins. Eighteen microarray probes mapping to fifteen SNORD 115 transcripts derived from cytoband 15q11.2 were upregulated, as were SNORD29, SNORD44, SNORD54 and SNORA73A (from the H/ACA group of snoRNAs).

10.1371/journal.pone.0028577.t004

###### Genes changed ≥4 fold (log 2 base ≥2) between 12 and 0 months no omentectomy.
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  Probe ID    Gene Symbol                     Gene Description                                Process                 Cytoband     mRNA Accession    log2fold
  ---------- ------------- ------------------------------------------------------ -------------------------------- -------------- ----------------- ----------
  7908650        IGFN1                     eEF1A2 binding protein                         protein turnover             1q32.1         NM_178275      −2.55556
  8012949       FBXW10            F-box and WD repeat domaincontaining 10                 protein turnover             17p12       ENST00000308799   2.06496
  7942476        PAAF1             proteasomal ATPase-associated factor 1                 protein turnover            11q13.4         NM_025155      2.01504
  7921690        ITLN1       intelectin 1 (galactofuranosebinding) (omentin -1)          insulin signaling           1q22-q23.5       NM_017625      −2.23682
  8108370        EGR1                     early growth response 1                       transcription factor           5q31.1         NM_001964      −3.05413
  7975779         FOS       v-fos FBJ murine osteosarcoma viral oncogene homolog        transcription factor          14q24.3         NM_005252      −4.09474
  8029693        FOSB         FBJ murine osteosarcoma viraloncogene homolog B           transcription factor          19q13.32        NM_006732      −2.12644
  8026047        JUNB                       jun B proto-oncogene                        transcription factor          19p13.2         NM_002229      −2.38627
  8148317         MYC           v-myc myelocytomatosis viraloncogene homolog            transcription factor          8q24.21         NM_002467      −2.0096
  7955858       HOXC10                          homeobox C10                            transcription factor          12q13.3         NM_017409       2.0778
  8006433        CCL2                  chemokine (C-C motif) ligand 2                       inflammation            17q11.2-q12       NM_002982      −2.09334
  8175531        CDR1         cerebellar degeneration-relatedprotein 1, 34kDa               inflammation            Xq27.1-q27.2      NM_004065      −3.36346
  8086344       CX3CR1              chemokine (C-X3-C motif) receptor 1                     inflammation            3p21\|3p21.3      NM_001337      2.12768
  8131803         IL6                interleukin 6 (interferon, beta 2)                     inflammation                7p21          NM_000600      −2.57781
  8156848        NR4A3         nuclear receptor subfamily 4,group A, member 3             orphan receptor               9q22          NM_173198      −2.72922
  7899480      SNORA73A              small nucleolar RNA, H/ACA box 73A            small nucleolar RNA expression      1p36.1         NR_002907      2.48545
  7982038     SNORD115-1             small nucleolar RNA, C/D box 115-1            small nucleolar RNA expression     15q11.2         NR_001291      2.68633
  7982078     SNORD115-11           small nucleolar RNA, C/D box 115-11            small nucleolar RNA expression     15q11.2         NR_003303      2.45315
  7982024     SNORD115-12           small nucleolar RNA, C/D box 115-12            small nucleolar RNA expression     15q11.2         NR_003304      2.54694
  7982050     SNORD115-12           small nucleolar RNA, C/D box 115-12            small nucleolar RNA expression     15q11.2         NR_003304      2.53634
  7982084     SNORD115-12           small nucleolar RNA, C/D box 115-12            small nucleolar RNA expression     15q11.2         NR_003304      2.03653
  7982008     SNORD115-13           small nucleolar RNA, C/D box 115-13            small nucleolar RNA expression     15q11.2         NR_003305      2.68633
  7982032     SNORD115-16           small nucleolar RNA, C/D box 115-16            small nucleolar RNA expression     15q11.2         NR_003308      2.68633
  7982046     SNORD115-20           small nucleolar RNA, C/D box 115-20            small nucleolar RNA expression     15q11.2         NR_003312      2.56052
  7982052     SNORD115-23           small nucleolar RNA, C/D box 115-23            small nucleolar RNA expression     15q11.2         NR_003315      3.03821
  7982056     SNORD115-25           small nucleolar RNA, C/D box 115-25            small nucleolar RNA expression     15q11.2         NR_003342      2.77049
  7982058     SNORD115-26           small nucleolar RNA, C/D box 115-26            small nucleolar RNA expression     15q11.2         NR_003343      2.46435
  7982028     SNORD115-43           small nucleolar RNA, C/D box 115-43            small nucleolar RNA expression     15q11.2         NR_003358      2.45315
  7982094     SNORD115-44           small nucleolar RNA, C/D box 115-44            small nucleolar RNA expression     15q11.2         NR_003359      2.75753
  7982016     SNORD115-5             small nucleolar RNA, C/D box 115-5            small nucleolar RNA expression     15q11.2         NR_003297      2.54694
  7982018     SNORD115-6             small nucleolar RNA, C/D box 115-6            small nucleolar RNA expression     15q11.2         NR_003298      2.30491
  7982090     SNORD115-6             small nucleolar RNA, C/D box 115-6            small nucleolar RNA expression     15q11.2         NR_003298      2.27704
  7982020     SNORD115-7             small nucleolar RNA, C/D box 115-7            small nucleolar RNA expression     15q11.2         NR_003299      3.00484
  7982092     SNORD115-9             small nucleolar RNA, C/D box 115-9            small nucleolar RNA expression     15q11.2         NR_003301      2.45315
  7948902       SNORD29               small nucleolar RNA, C/D box 29              small nucleolar RNA expression      11q13          NR_002559      2.34649
  7922410       SNORD44               small nucleolar RNA, C/D box 44              small nucleolar RNA expression      1q25.1         NR_002750      2.10829
  8150877       SNORD54               small nucleolar RNA, C/D box 54              small nucleolar RNA expression       8q12          NR_002437      2.06555
  7902687        CYR61             cysteine-rich, angiogenic inducer, 61                extracellular matrix          1p31-p22        NM_001554      −2.6069
  8106573        THBS4                        thrombospondin 4                          extracellular matrix            5q13          NM_003248      −2.07002
  8042788        ACTG2             actin, gamma 2, smooth muscle, enteric                      other                   2p13.1         NM_001615      −2.1841
  7931832       AKR1C2            aldo-keto reductase family 1, member C2                      other                 10p15-p14        NM_205845      2.20199
  7924821        gm127                  similar to RIKEN 2610020C11                            other                  1q42.13         AF387613        −2.183
  8048014         RPE                 ribulose-5-phosphate-3-epimerase                         other                 2q32-q33.3       NM_199229      2.17662

Skeletal muscle gene expression changes with omentectomy {#s3f}
--------------------------------------------------------

At 6 vs. 0 months in the RYGB with omentectomy group, the number of genes differentially expressed in muscle was nearly double that observed in the RYGB without omentectomy cohort at the same time point. [**Table 5**](#pone-0028577-t005){ref-type="table"} lists the 46 genes that expressed greater than a 4-fold change. Genes known to be involved in facilitating the inflammatory response were particularly responsive. In addition to ANKRD1, CCL2, and IL6 observed as being greater than 4-fold downregulated in the RYGB without omentectomy group, the inflammatory genes CH25H, CXCL2, SOCS3, IL8, LBP, NFIL3, SELE and TNFAIP3 also were downregulated. All of the transcription factors differentially expressed at 6 months in the non-omentectomy group were also downregulated in the 6 months with omentectomy group, as was ATF3. Adiponectin (ADIPOQ) and the glucose transporter (SLC2A3) genes along with the extracellular matrix proteins ADAM metallopeptidase 1 and 4 (ADAMTS1 and ADAMTS4), CYR61, CD54, THBD and THBS1 were all downregulated; however a handful of genes with varied functions (ATRX, DLEU2, ZNF780B, YIPF7, RWDD3, ANGPT1) were upregulated. All 3 members of the nuclear orphan nuclear receptor family 4 (NRFA1-3) recently identified as controlling skeletal muscle metabolism [@pone.0028577-Pearen1], [@pone.0028577-Pearen2] were downregulated; in particular NR4A3 which was downregulated over 12 fold. Similar phenomena were observed in the 12 vs. 0 months with omentectomy group as were found at 6 vs. 0 months with omentectomy group. A subset of other proteins with varying functions complete the list of genes with differential expression values greater than 4 fold; in total 36 genes were observed ([**Table 6**](#pone-0028577-t006){ref-type="table"} **)**.

10.1371/journal.pone.0028577.t005

###### Genes changed ≥4 fold (log 2 base ≥2) between 6 and 0 months with omentectomy.
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  Probe ID    Gene Symbol                         Gene Description                                    Process                 Cytoband      mRNA Accession   log2fold
  ---------- ------------- -------------------------------------------------------------- -------------------------------- --------------- ---------------- ----------
  7908650        IGFN1                         eEF1A2 binding protein                             protein turnover             1q32.1         NM_178275      −3.10661
  8108370        EGR1                         early growth response 1                           transcription factor           5q31.1         NM_001964      −4.47459
  7975779         FOS           v-fos FBJ murine osteosarcoma viraloncogene homolog             transcription factor           14q24.3        NM_005252      −5.12292
  8029693        FOSB             FBJ murine osteosarcoma viraloncogene homolog B               transcription factor          19q13.32        NM_006732      −2.78581
  8026047        JUNB                           jun B proto-oncogene                            transcription factor           19p13.2        NM_002229      −3.56001
  8148317         MYC           v-myc myelocytomatosis viraloncogene homolog (avian)            transcription factor           8q24.21        NM_002467      −3.08841
  7909610        ATF3                    activating transcription factor 3                      transcription factor           1q32.3        NM_001040619    −2.23226
  8084710       ADIPOQ            adiponectin, C1Q and collagen domain containing                insulin signaling              3q27          NM_004797      −2.25931
  7960865       SLC2A3      solute carrier family 2 (facilitated glucose transporter), 3         insulin signaling             12p13.3        NM_006931      −2.60975
  7934979       ANKRD1                ankyrin repeat domain 1 (cardiac muscle)                      inflammation              10q23.31        NM_014391      −2.57698
  8006433        CCL2                  chemokine (C-C motif) ligand 2 (MCP-1)                       inflammation             17q11.2-q12      NM_002982      −3.85999
  7934916        CH25H                       cholesterol 25-hydroxylase                             inflammation                10q23         NM_003956      −2.56701
  8100994        CXCL2               chemokine (C-X-C motif) ligand 2 (MIP-2a)                      inflammation                4q21          NM_002089      −2.61796
  8131803         IL6                    interleukin 6 (interferon, beta 2)                         inflammation                7p21          NM_000600      −5.01826
  8018864        SOCS3                   suppressor of cytokine signaling 3                         inflammation               17q25.3        NM_003955      −3.40317
  8095680         IL8                              interleukin 8                                    inflammation              4q13-q21        NM_000584      −2.02015
  8062461         LBP                    lipopolysaccharide binding protein                         inflammation            20q11.23-q12      NM_004139      −2.16848
  8162276        NFIL3                nuclear factor, interleukin 3 regulated                       inflammation                9q22          NM_005384      −2.63846
  7922229        SELE               selectin E (endothelial adhesion molecule 1)                    inflammation              1q22-q25        NM_000450      −2.46165
  8122265       TNFAIP3            tumor necrosis factor, alpha-induced protein 3                   inflammation                6q23          NM_006290      −2.0769
  8028652        ZFP36            zinc finger protein 36, C3H type,homolog (mouse)                  inflammation               19q13.1        NM_003407      −2.36152
  7955589        NR4A1             nuclear receptor subfamily 4, group A,member 1                 orphan receptor               12q13         NM_002135      −2.36834
  8055952        NR4A2             nuclear receptor subfamily 4, group A,member 2                 orphan receptor             2q22-q23        NM_006186      −2.11225
  8156848        NR4A3             nuclear receptor subfamily 4, group A,member 3                 orphan receptor               9q22          NM_173198      −3.65489
  7929816         SCD               stearoyl-CoA desaturase (delta-9-desaturase)               fatty acid metabolism          10q23-q24       NM_005063      −2.69181
  7920873       SNORA42                  small nucleolar RNA, H/ACA box 42                 small nucleolar RNA expression       1q22          NR_002974      −2.13869
  8069676       ADAMTS1        ADAM metallopeptidasew/thrombospondin type 1 motif, 1        extracellular matrix protein       21q21.2        NM_006988      −2.77417
  7921821       ADAMTS4        ADAM metallopeptidasew/thrombospondin type 1 motif, 4        extracellular matrix protein      1q21-q23        NM_005099      −2.82585
  7902687        CYR61                 cysteine-rich, angiogenic inducer, 61                extracellular matrix protein      1p31-p22        NM_001554      −2.94737
  8025601        ICAM1                intercellular adhesion molecule 1 (CD54)              extracellular matrix protein    19p13.3-p13.2     NM_000201      −2.25818
  8065353        THBD                              thrombomodulin                           extracellular matrix protein       20p11.2        NM_000361      −2.80578
  7982597        THBS1                            thrombospondin 1                          extracellular matrix protein        15q15         NM_003246      −3.01553
  8152297       ANGPT1                             angiopoietin 1                                      other                 8q22.3-q23       NM_001146      2.01173
  8176276        ATRX          alpha thalassemia/mental retardationsyndrome X-linked                   other                Xq13.1-q21.1      NM_138270      2.62294
  8086330        AXUD1                          AXIN1 up-regulated 1                                   other                    3p22          NM_033027      −2.06593
  8119088       CDKN1A            cyclin-dependent kinase inhibitor 1A(p21, Cip1)                      other                   6p21.2         NM_078467      −2.02657
  7971653        DLEU2                   deleted in lymphocytic leukemia, 2                            other                   13q14.3        NR_002612      2.22215
  8024485       GADD45B             growth arrest and DNA-damage-inducible, beta                       other                   19p13.3        NM_015675       −2.811
  7954090        EMP1                      epithelial membrane protein 1                               other                   12p12.3        NM_001423      −2.17339
  7995806        MT1A                            metallothionein 1A                                 antioxidant                 16q13          AY028617      −2.5602
  7995787        MT1M                            metallothionein 1M                                 antioxidant                 16q13         NM_176870      −2.49124
  7903171        RWDD3                        RWD domain containing 3                                  other                   1p21.3         NM_015485      2.03845
  8135069      SERPINE1                                                                                other                 7q21.3-q22       NM_000602      −2.67627
  8070665       SNF1LK                            SNF1-like kinase                                     other                   21q22.3        NM_173354      −2.38371
  8100076        YIPF7                      Yip1 domain family, member 7                               other                    4p13          NM_182592      2.07083
  8036813       ZNF780B                       zinc finger protein 780B                                 other                   19q13.2       NM_001005851     2.1765

10.1371/journal.pone.0028577.t006

###### Genes changed ≥4 fold (log 2 base ≥2) between 12 and 0 months with omentectomy.
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  Probe ID    Gene Symbol                              Gene Description                                    Process            Cytoband     mRNA Accession   log2fold
  ---------- ------------- ------------------------------------------------------------------------ ---------------------- -------------- ---------------- ----------
  7908650        IGFN1                              eEF1A2 binding protein                             protein turnover        1q32.1        NM_178275      −2.33443
  8108370        EGR1                              early growth response 1                           transcription factor      5q31.1        NM_001964      −4.20485
  7975779         FOS                v-fos FBJ murine osteosarcoma viral oncogenehomolog             transcription factor     14q24.3        NM_005252       −5.064
  8029693        FOSB                  FBJ murine osteosarcoma viral oncogene homolog B              transcription factor     19q13.32       NM_006732      −2.66602
  8026047        JUNB                                jun B proto-oncogene                            transcription factor     19p13.2        NM_002229      −3.42952
  8148317         MYC                v-myc myelocytomatosis viral oncogenehomolog (avian)            transcription factor     8q24.21        NM_002467      −3.13093
  7955858       HOXC10                                   homeobox C10                                transcription factor     12q13.3        NM_017409      2.15884
  7902687        CYR61                      cysteine-rich, angiogenic inducer, 61                     insulin signaling       1p31-p22       NM_001554      −2.51451
  8163002        KLF4                            Kruppel-like factor 4 (gut)                          insulin signaling         9q31         NM_004235      −2.04104
  7960865       SLC2A3         solute carrier family 2 (facilitated glucosetransporter) member3       insulin signaling       12p13.3        NM_006931      −2.51532
  7934979       ANKRD1                     ankyrin repeat domain 1 (cardiac muscle)                      inflammation         10q23.31       NM_014391      −3.4932
  8006433        CCL2                           chemokine (C-C motif) ligand 2                           inflammation       17q11.2-q12      NM_002982      −3.21861
  7934916        CH25H                            cholesterol 25-hydroxylase                             inflammation          10q23         NM_003956      −2.42635
  8100994        CXCL2                         chemokine (C-X-C motif) ligand 2                          inflammation           4q21         NM_002089      −2.2466
  8162276        NFIL3                     nuclear factor, interleukin 3 regulated                       inflammation           9q22         NM_005384      −2.47028
  7922229        SELE                    selectin E (endothelial adhesion molecule 1)                    inflammation         1q22-q25       NM_000450      −2.42547
  8018864        SOCS3                        suppressor of cytokine signaling 3                         inflammation         17q25.3        NM_003955      −3.36272
  8122265       TNFAIP3                 tumor necrosis factor, alpha-induced protein 3                   inflammation           6q23         NM_006290      −2.15921
  8028652        ZFP36                 zinc finger protein 36, C3H type, homolog(mouse)                  inflammation         19q13.1        NM_003407      −2.21499
  8131803         IL6                         interleukin 6 (interferon, beta 2)                         inflammation           7p21         NM_000600      −5.07812
  8062461         LBP                         lipopolysaccharide binding protein                         inflammation       20q11.23-q12     NM_004139      −2.13523
  8025828        LDLR          low density lipoprotein receptor (familial hypercholesterolemia)           receptors           19p13.3        NM_000527      −2.22451
  7955589        NR4A1                 nuclear receptor subfamily 4, group A, member 1                    receptors            12q13         NM_002135      −2.04616
  8156848        NR4A3                 nuclear receptor subfamily 4, group A, member 3                    receptors             9q22         NM_173198      −3.6856
  8069676       ADAMTS1            ADAM metallopeptidase with thrombospondintype 1 motif, 1          extracellular matrix     21q21.2        NM_006988      −3.41834
  7921821       ADAMTS4            ADAM metallopeptidase with thrombospondintype 1 motif, 4          extracellular matrix     1q21-q23       NM_005099      −2.4919
  8065353        THBD                                   thrombomodulin                               extracellular matrix     20p11.2        NM_000361      −2.61527
  7982597        THBS1                                 thrombospondin 1                              extracellular matrix      15q15         NM_003246      −3.12862
  8086330        AXUD1                               AXIN1 up-regulated 1                                   other               3p22         NM_033027      −2.08176
  8084206       B3GNT5            UDP-GlcNAc:betaGal β-1,3-N-acetylglucosaminyltransferase 5                other               3q28         NM_032047      −2.25232
  7954090        EMP1                           epithelial membrane protein 1                               other             12p12.3        NM_001423      −2.14602
  8024485       GADD45B                  growth arrest and DNA-damage-inducible, beta                       other             19p13.3        NM_015675      −2.47919
  8086538      LOC644714                        hypothetical protein LOC644714                              other             3p21.31         BC047037      −2.13574
  7995806        MT1A                                 metallothionein 1A                                    other              16q13          AY028617      −2.47681
  7995787        MT1M                                 metallothionein 1M                                    other              16q13         NM_176870      −2.24145
  8135069      SERPINE1     serpin peptidase inhibitor, E1 (plasminogenactivator inhibitor type 1)          other            7q21.3-q22      NM_000602      −2.56719

Effects of omentectomy evaluated by global pathway analysis {#s3g}
-----------------------------------------------------------

To identify pathways in skeletal muscle that were regulated by RYGB with and without omentectomy we performed two complimentary analyses. For these analyses those genes detected as being changed greater than 2-fold (2,697 genes; **[Table S1](#pone.0028577.s003){ref-type="supplementary-material"}**) were analyzed. First, the gene list was analyzed by the FuncAssociate Gene Ontology program (<http://llama.mshri.on.ca/funcassociate/>) to statistically identify overrepresented gene categories [@pone.0028577-Berriz1]. Cadmium ion binding (GO:0046870), positive regulation of leukocyte binding (GO:0002687) and cellular macromolecule catabolic processes (GO:0044265) were top ranked. Second, we annotated our expression data with the wiring diagrams of molecular interactions, reactions, and relations maintained at the Kyoto Encyclopedia of Genes and Genomes (KEGG) PATHWAY Database. As reported in **[Table S4](#pone.0028577.s006){ref-type="supplementary-material"}**, coverage of 201 pathways by our experimental datasets revealed that *metabolic pathways, cytokine-cytokine receptor interaction*, *MAPK signaling pathways, chemokine signaling pathways, and spliceosome* were top ranked.

Validation of microarray expression profiles with TLDA {#s3h}
------------------------------------------------------

As the significance of gene expression changes determined with microarray could not be determined empirically due to the low number of array replicates, and because a single outlier sample within an RNA pool could in theory skew results, we elected to validate the expression changes of select genes in each of the individual RNA samples comprising the RNA pools using Taqman Low Density Arrays (TLDA). In addition to the RNA samples used to prepare the RNA pools, we also included RNA samples prepared from additional participants lacking a single study (either 6 or 12 months) time point RNA sample. Using a spot checking strategy, expression of 31 genes was used to validate differential expression data discovered during the microarray study (**[Table S2](#pone.0028577.s004){ref-type="supplementary-material"}**). This approach is admittedly restrictive; however, we focused on genes involved in pathways such as inflammation, transcriptional regulation, protein turnover and insulin signaling [@pone.0028577-Kewalramani1], [@pone.0028577-Olefsky1]. Gene selection was guided based on literature reviews of the effects of weight loss on skeletal muscle, our recent report that omentectomy concurrent with RYGB did not improve muscle insulin sensitivity [@pone.0028577-Fabbrini1], and recent observations that altered intramuscular lipid metabolism, circulating cytokines and macrophage infiltration may act synergistically to coordinate insulin sensitivity [@pone.0028577-Kewalramani1], [@pone.0028577-Olefsky1].

[**Figures 4**](#pone-0028577-g004){ref-type="fig"} **--** [](#pone-0028577-g005){ref-type="fig"} [](#pone-0028577-g006){ref-type="fig"} [**7**](#pone-0028577-g007){ref-type="fig"} show the relative average differential expression values determined by microarray (light grey) and TLDA (dark grey) for 31 genes, normalized to an 18S RNA control, when analyzed in triplicate at 0, 6 and 12 months. Of the 5,184 Taqman analyses performed to validate select microarray-derived expression values, only 3 reactions did not amplify. In general, there was good directional (increased or decreased) concordance between expression values derived from analysis of pooled RNA samples and the average of each RNA sample analyzed independently. In most instances, fold expression change values determined by exon array in pooled RNA samples were greater than the averages of individual expression values obtained by TLDA (e.g. FOSB, EGR and IL6 in [**Figures 4**](#pone-0028577-g004){ref-type="fig"} **--** [](#pone-0028577-g005){ref-type="fig"} [](#pone-0028577-g006){ref-type="fig"} [**7**](#pone-0028577-g007){ref-type="fig"}). We examined the relationship between gene expression values revealed by exon array and TLDA profiling. In all group comparisons, there were strong positive relationships: 1) 6 vs. 0 months without omentectomy rho = 0.559 ([**Figure 8A**](#pone-0028577-g008){ref-type="fig"} **)**; 12 vs. 0 months without omentectomy rho = 0.720 ([**Figure 8B**](#pone-0028577-g008){ref-type="fig"}); 6 vs. 0 months with omentectomy rho = 0.646 ([**Figure 8C**](#pone-0028577-g008){ref-type="fig"}); and 12 vs. 0 months with omentectomy rho = 0.640 ([**Figure 8D**](#pone-0028577-g008){ref-type="fig"}).

![Bar graph illustrating the fold change of individual genes at 6 vs. 0 months without omentectomy as determined by microarray (grey) and TLDA profiling (black).](pone.0028577.g004){#pone-0028577-g004}

![Bar graph illustrating the fold change of individual genes at 12 vs. 0 months without omentectomy as determined by microarray (grey) and TLDA profiling (black).](pone.0028577.g005){#pone-0028577-g005}

![Bar graph illustrating the fold change of individual genes at 6 vs. 0 months with omentectomy as determined by microarray (grey) and TLDA profiling (black).](pone.0028577.g006){#pone-0028577-g006}

![Bar graph illustrating the fold change of individual genes at 12 vs. 0 months with omentectomy as determined by microarray (grey) and TLDA profiling (black).](pone.0028577.g007){#pone-0028577-g007}

![Correlation in fold change (log~2~) of gene expression as determined by Affymetrix Exon microarray and TLDA profiling.\
A) 6 vs. 0 months, no omentectomy, Pearson correlation coefficient rho = 0.559, *p*\<0.0001; B) 12 vs. 0 months, no omentectomy, Pearson correlation coefficient rho = 0.646, *p* = 0.0002; C) 6 vs. 0 months, yes omentectomy, Pearson correlation coefficient rho = 0.649, *p* = 0.0002; D) 12 vs. 0 months, yes omentectomy, Pearson correlation coefficient rho = 0.640, *p* = 0.0002.](pone.0028577.g008){#pone-0028577-g008}

Discussion {#s4}
==========

This is the first high-throughput study to explore the temporal changes in human skeletal muscle gene expression after weight loss through RYGB surgery with tandem laparoscopic omentectomy. In addition, randomization of subjects to removal of the omentum at the time of RYGB allowed us to explore the interplay between visceral adipose and skeletal muscle. While the effects of bariatric surgery on gene expression in muscle have been reported for a few targets [@pone.0028577-Adami1], [@pone.0028577-Greco2], [@pone.0028577-Johansson1], [@pone.0028577-Leichman1], the influence of the omentum (visceral adipose) on global skeletal muscle phenotypes (such as insulin resistance) has been understudied. Visceral adipose is the source of 14--20% of the total FFAs delivered to skeletal muscle in obese individuals [@pone.0028577-Klein1], [@pone.0028577-Nielsen1] and numerous studies have linked circulating FFA levels and muscle triglyceride accumulation with peripheral insulin sensitivity [@pone.0028577-Bajaj1], [@pone.0028577-CameronSmith1], [@pone.0028577-Hegarty1], [@pone.0028577-HeronMilhavet1]. Visceral adipose tissue is also the site of production of several cytokines thought to initiate and maintain pro-inflammatory states both locally and in other tissues [@pone.0028577-Donohoe1]. Infiltration and local activation of macrophages in skeletal muscle also has been described [@pone.0028577-Kewalramani1], [@pone.0028577-Olefsky1]. Our group recently reported, in the same subjects examined in the present study, that laparoscopic removal of the greater omentum at the time of RYGB did not significantly enhance weight loss-induced improvements in peripheral insulin sensitivity beyond those observed with RYGB alone [@pone.0028577-Fabbrini1]. These findings were unanticipated in light of the numerous studies associating increased visceral adiposity with insulin resistance and T2D [@pone.0028577-Colberg1], [@pone.0028577-Macor1], [@pone.0028577-Coker1]. Despite these findings, it remained possible that omentectomy produced local changes at the level of the muscle that may not be totally reflected with associated improvements in peripheral glucose utilization. The Affymetrix Exon arrays and TLDA approaches utilized in this study provided a robust and reproducible technique for quantifying gene expression in thousands of independent genes concurrently in RNA samples isolated from multiple tissue samples. This approach represents a significant advance in multivariate gene analysis that was less time- and labor-intensive than individually analyzing single genes by quantitative RT-PCR.

Our major finding was a broad-based downregulation of inflammatory-related pathways in skeletal muscle after RYGB surgery. This response was amplified in the cohort receiving omentectomy, as evidenced by a greater number of genes with at least a 4-fold decrease at 6 or 12 months (at least 4 genes in the RYGB non-omentectomy cohort compared to 11 in the RYGB with omentectomy cohort). Most of the observed inflammatory genes that were only decreased in the RYGB with omentectomy cohort are reportedly associated with macrophage activation (CH25H, CXCL2, SOCS3, LBP, NFIL3, ZFP36) [@pone.0028577-Park2], [@pone.0028577-Wolpe1], [@pone.0028577-Yoshimura1], [@pone.0028577-Grube1], [@pone.0028577-Hubal1], consistent with the systemic decrease in MCP-1, or associated with inflammatory events surrounding sarcopenia (ANKRD1, LBP) [@pone.0028577-Badi1], [@pone.0028577-Oropeza1]. Certain genes such as IL6 and CCL2 were decreased in both groups at both time points relative to pre-surgery levels, but the reductions were greater in the omentectomy group. Changes in IL6 expression levels at 6 and 12 months in the RYGB with omentectomy cohort were the greatest of any gene detected. IL6 is a pleiotropic cytokine described to impact insulin action [@pone.0028577-Franckhauser1], [@pone.0028577-Holmes1]. IL-6 infusion reportedly increased fatty acid oxidation in human skeletal muscle but not adipose tissue, suggesting a role for this cytokine in stimulating skeletal muscle lipolysis specifically [@pone.0028577-Wolsk1]. In the current study, despite glucose utilization (M) being significantly improved at both time-points, omentectomy did not have a differential effect. Interestingly, systemic levels of IL-6 did not change after RYGB. In contrast, other cytokines such as CX3CR1 [@pone.0028577-TeranGarcia1] were equally diminished at 6 and 12 months in both groups after RYGB. Circulating monocytes with high levels of CX3CR1 (frataxylin), are present in systemic disease, such as sepsis or HIV infection, while the macrophage subset that invades tissues during acute localized inflammation expresses lower levels of CX3CR1. These data provide evidence that RYGB reduces the local inflammatory response in muscle which is enhanced by omentectomy, and the physiological consequences warrant further study.

The expression of several transcription factors involved in proliferation control, (FOS, FOSB, JUNB, MYC and EGR1) was reduced at 6 and 12 months after RYGB in both RYGB cohorts with and without omentectomy. These five genes were among those that showed the greatest drop in expression post-RYGB, and their decrease was greater in the omentectomy cohort at both time-points. FOS, FOSB and JUNB are intermediate early genes comprising the AP-1 basic leucine zipper transcription factor family that act on specific biological responses to regulate gene expression. Each has been shown to be increased immediately after exercise [@pone.0028577-Puntschart1], but this study is the first to associate them with changes in skeletal muscle after RYGB. Adipose-specific overexpression of ΔFOSB, a naturally occurring alternatively spliced variant of FosB that is antagonistic to normal FosB-mediated gene transcription, was recently shown to increase energy expenditure in muscle and increase insulin sensitivity [@pone.0028577-Rowe1]. Expression of EGR1, a GC box-binding transcription factor, has been shown to regulate TGF-β expression which, in turn increases myostatin expression [@pone.0028577-Irrcher1]. The expression of EGR-1 was decreased over 4-fold in the omentectomy cohorts compared to the 2- and 3-fold reductions observed in the non-omentectomy cohort at 6 and 12 months, respectively. EGR-1 binding sites are prevalent in the promoter binding sites for genes such as peroxisomal gamma coactivator-1α (PGC-1α), that are important regulators of mitochondrial biogenesis [@pone.0028577-Freyssenet1]. The nuclear phosphoprotein MYC was decreased 3-fold at both 6 and 12 month time points in the RYGB with omentectomy cohort but only 2-fold at the same time points in the group without omentectomy. In contrast, HOXC10, a homeoprotein associated with muscle satellite cell activation was upregulated over 2-fold at 12 months in both cohorts, and at 6 months in the RYGB with omentectomy group. The protein product of this gene, together with Pax7, Asb5 and IgSF4, was shown to be markers for skeletal muscle satellite cells [@pone.0028577-Seale1]. In the present study, increased HOXC10 expression at all time points in both cohorts implies that muscle satellite cell activation and deactivation of transcriptional responses are an important phenomenon in muscle remodeling, particularly after weight loss.

Genes facilitating extracellular matrix (ECM) remodeling such as CYR61, THBS1 and THBS4 were downregulated, consistent with an improvement in inflammation. High levels of muscle expression of ECM, inflammatory, and immediate early genes in obesity could indicate a continual, unsuccessful attempt to repair muscle damage caused by fat overload. A role for the ECM in insulin resistance has been described but is largely unappreciated. Infusion of FFA in subjects with normal glucose tolerance has been shown to increase the expression of ECM genes in muscle coincident with a decrease in insulin sensitivity [@pone.0028577-Richardson1]; furthermore, animal studies indicate that ECM expansion contributes to insulin resistance [@pone.0028577-Kang1]. These studies in concert with our current results indicate that further studies connecting obesity, the ECM, and insulin resistance are warranted.

Three genes annotated as regulating protein turnover were significantly altered upon RYGB in both surgical groups. The gene encoding eEF1A2 binding protein (IGFN1 or Dkfzp434B1231) plays a key role in protein translation, carrying each aminoacyl-transfer RNA complex to the A site of the ribosome after codon-anticodon recognition [@pone.0028577-Murray1]. In cultured myotubes, IGFN1 expression inhibited apoptosis and promoted cell proliferation in hyper-catabolic trauma patients [@pone.0028577-Bosutti1] and was required for the muscle-specific expression of utrophin A, a sarcomellar protein causal in the fatal neuromuscular disease Duchenne Muscular Dystrophy [@pone.0028577-Miura1]. In our studies IGNF1 expression was reduced greater than 4-fold, a pattern consistent with muscle catabolism known to occur in this population. Other genes involved in protein turnover such as FBXW10, a component of the E3 ubiquitin ligase system that determines substrate specificity during proteasomal degradation, demonstrated an increased expression pattern primarily at the 12-month time point. It seems likely that as a result of RYGB the regulation of muscle protein maintenance is upset. Future studies in this population examining muscle protein synthesis and muscle protein breakdown using state-of-the-art isotopic tracer methodologies may delineate mechanisms contributory to this observation.

At 6 and 12 months after RYGB in the non-omentectomy group, several small nucleolar RNAs from the C/D box group (SNORDs) were among the few genes that were upregulated in skeletal muscle. SNORDs are a class of small RNA non-protein coding micro RNAs that molecules that guide chemical modification, particularly 2′-O-methylation [@pone.0028577-Galardi1] and alternative splicing [@pone.0028577-Kishore1] of other RNAs. Interestingly, the absence of small nucleolar RNA C/D box 115 gene expression units have been implicated as causal in Prader-Willi Syndrome [@pone.0028577-Cavaille1], the most common form of monogenetic obesity. Previous studies, however, indicate that expression of HBII-52 is restricted to the brain [@pone.0028577-Cavaille1]; thus, the relevance of the observed expression of SNORD 115 variants in muscle and the increased expression after RYGB is highly unclear.

We have identified a set of genes, which were significantly and differentially altered after RYGB with and without omentectomy; however, there are some important limitations to this study. First, while the utmost effort was placed on ensuring the quality of the muscle biopsies used for RNA extraction both before and after surgery, it remains possible that some intercalated adipose, adventitia and/or microvasculature may have been present in some tissues. This phenomenon was more likely in biopsies obtained prior to RYGB surgery, compared to those at either time point after surgery when significant weight loss occurred, and may lead to significant gene expression changes that are not exclusive to skeletal muscle. For example, the observed changes in adiponectin (ADIPOQ) and omentin-1 (ITLN1) might be reflective of intercalated adipose tissue as this is their primary site of production, although muscle specific expression has been reported [@pone.0028577-Yang1]. Thirdly, we elected to use Robust Multi-array Averaging, a common normalization method, but did not perform the default quantile across sample normalization method of RMA to avoid over-correction for the small sample size. The data were also analyzed without adjustments for multiplicity, which could alter differential expression estimates [@pone.0028577-Bullard1]. Nevertheless, our validation efforts focused primarily on those genes affected 4 fold or greater (log~2~ -- 2 fold) and, as such, any misinterpretations based on this should be minimal. Finally, we are unable to account for the extrinsic factors, other than those reported in [**Tables 1**](#pone-0028577-t001){ref-type="table"} and [**2**](#pone-0028577-t002){ref-type="table"} that can affect end-organ metabolic response. As RYGB surgery is a procedure known for its systemic and interconnected effects on hormonal, neuronal, and biochemical impulses, the discrimination of a muscle-specific response due solely to the removal of omentum remains a challenge.

With regard to our overall study design, there are some limitations that should be mentioned. The population studied was reflective of Nashville, TN and the surrounding counties with an ethnic distribution (Caucasians to African Americans) of 4∶1. While both the omentectomy and non-omentectomy group contained participants with and without T2D, the proportion of subjects with T2D was unequal between groups. There were also no Hispanics in the studied cohorts, based on our geographic locale, and the subjects studied were also primarily female reflective of the patient population seeking this surgical approach; therefore, our findings may be gender and ethnically limited.
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